E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Leroi
M J
MJ
Department of Microbiology and Infectious Diseases, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Siarakas
S
S
Gottlieb
T
T
D000081:Acetamides / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D016360:Clostridioides difficile / Q000187:drug effects* / Q000302:isolation & purification; D003015:Clostridium Infections / Q000188:drug therapy / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D003967:Diarrhea / Q000188:drug therapy / Q000382:microbiology; D024841:Fluoroquinolones; D005672:Fusidic Acid / Q000494:pharmacology*; D000077734:Gatifloxacin; D006801:Humans; D000069349:Linezolid; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D023303:Oxazolidinones / Q000494:pharmacology; D011804:Quinolines; D012680:Sensitivity and Specificity; D014640:Vancomycin / Q000494:pharmacology*
D000081:Acetamides; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011804:Quinolines; D008795:Metronidazole; D005672:Fusidic Acid; D014640:Vancomycin; D000069349:Linezolid; D000077734:Gatifloxacin; D000077266:Moxifloxacin